John Patrick Darby
Known title: EVP, Gen Counsel & SecretaryCIK: 0001664699
Associated companies
Transaction History
| EHC | ▲ Buy | Option Exercise | 4,858 | $170K | 8/31/2026 | View on chart |
| EHC | ▼ Sell | Open Market | 4,858 | $588K | 8/31/2026 | View on chart |
| EHC | ▼ Sell | Open Market | 8,906 | $1.1M | 8/10/2026 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 416 | $45K | 2/28/2026 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 6,990 | $742K | 2/23/2026 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 328 | $35K | 2/20/2026 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 7,903 | $847K | 2/19/2026 | View on chart |
| EHC | ▲ Buy | Grant | 2,154 | $0 | 2/19/2026 | View on chart |
| EHC | ▲ Buy | Grant | 17,720 | $0 | 2/18/2026 | View on chart |
| EHC | ▲ Buy | Option Exercise | 10,000 | $351K | 4/29/2025 | View on chart |
| EHC | ▼ Sell | Open Market | 10,000 | $1.1M | 4/29/2025 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 416 | $42K | 2/28/2025 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 509 | $51K | 2/25/2025 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 437 | $43K | 2/24/2025 | View on chart |
| EHC | ▲ Buy | Grant | 2,216 | $0 | 2/20/2025 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 5,917 | $546K | 1/1/2025 | View on chart |
| EHC | ▲ Buy | Option Exercise | 14,543 | $423K | 5/6/2024 | View on chart |
| EHC | ▼ Sell | Open Market | 14,543 | $1.2M | 5/6/2024 | View on chart |
| EHC | ▲ Buy | Grant | 2,812 | $0 | 2/28/2024 | View on chart |
| EHC | ▲ Buy | Grant | 13,116 | $0 | 2/28/2024 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 509 | $38K | 2/25/2024 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 397 | $30K | 2/24/2024 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 437 | $33K | 2/23/2024 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 4,920 | $328K | 1/2/2024 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 509 | $31K | 2/27/2023 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 397 | $24K | 2/24/2023 | View on chart |
| EHC | ▲ Buy | Grant | 10,799 | $0 | 2/23/2023 | View on chart |
| EHC | ▲ Buy | Grant | 17,728 | $0 | 2/23/2023 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 369 | $23K | 2/21/2023 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 3,113 | $186K | 1/3/2023 | View on chart |
| EHC | ▲ Buy | Grant | 5,572 | $0 | 2/25/2022 | View on chart |
| EHC | ▲ Buy | Grant | 2,854 | $0 | 2/25/2022 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 330 | $22K | 2/24/2022 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 673 | $44K | 2/22/2022 | View on chart |
| EHC | ▼ Sell | Tax Withholding | 2,537 | $166K | 1/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Encompass Health Sets Q3 2026 Earnings Call Date
Encompass Health announced the date for its 2026 third-quarter earnings call. Recent coverage also highlights the company's small-format expansion strategy and potential undervaluation as it builds out its rehabilitation capacity. The stock is currently trading near the lower end of its 52-week range, with an average analyst target of $148.17.
Encompass Health Sets Q3 2026 Earnings Call Date. Encompass Health announced the date for its 2026 third-quarter earnings call. Recent coverage also highlights the company's small-format expansion strategy and potential undervaluation as it builds out its rehabilitation capacity. The stock is currently trading near the lower end of its 52-week range, with an average analyst target of $148.17.